Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

EGFR · Non-Small Cell Lung Cancer · Locally Advanced Non-Small Cell Lung Cancer · Pemetrexed · Carboplatin · Bevacizumab · Antineoplastic Agents · Tyrosine Kinase Inhibitor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Yue Liu) · 18831402353@163.com · 18831402353

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Non Small Cell Lung Cancer · EGFR Gene Mutation · ALK Gene Mutation

Abroad (travel likely)RecruitingPHASE2

Changsha, China

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Beijing, China

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

NSCLC (Advanced Non-small Cell Lung Cancer) · EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Non-Small Cell Lung Cancer With EGFR Mutation

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Harbin, China